PWPS
CRSP icon

Pinnacle Wealth Planning Services’s CRISPR Therapeutics CRSP Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.61K Sell
160
-1
-0.6% -$53 ﹤0.01% 2117
2025
Q4 		$8.44K Buy
+161
New +$9.64K ﹤0.01% 2077

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pinnacle Wealth Planning Services's CRSP Position: Q1 2026 in Review

Pinnacle Wealth Planning Services reduced its CRISPR Therapeutics (CRSP) stake by 0.62% in Q1 2026, selling an estimated $53 and leaving 160 shares worth $7.61K. The position accounts for ﹤0.01% of the portfolio, ranked #2117.

Pinnacle Wealth Planning Services first reported a position in CRSP in Q4 2025 and has held it in 2 quarters since. The position peaked at $8.44K in Q4 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Pinnacle Wealth Planning Services held 160 shares of CRISPR Therapeutics worth $7.61K as of Q1 2026.
  • Pinnacle Wealth Planning Services sold 1 CRISPR Therapeutics share in Q1 2026, an estimated $53.
  • CRISPR Therapeutics made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q1 2026, its #2117 holding.
  • Pinnacle Wealth Planning Services first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Pinnacle Wealth Planning Services's CRISPR Therapeutics position peaked at $8.44K in Q4 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q1 2026, filed 11 May 2026.